Generative-AI drug developer Insilico Medicine said on Sunday that it has agreed a global licensing and research deal with US drugmaker Eli Lilly, that could be worth up to US$2.75 billion
Read MoreGenerative-AI drug developer Insilico Medicine said on Sunday that it has agreed a global licensing and research deal with US drugmaker Eli Lilly, that could be worth up to US$2.75 billion
Read More